Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 3Brain Neoplasms 3Neuroblastoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Gliosarcoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Aminolevulinic Acid 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × TPI-287 × Clear all
NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 7 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT02047214 2018-01-31

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Cortice Biosciences, Inc.

Phase 2 Terminated
17 enrolled
CNS

Glioblastoma

NCT01113463 2016-10-31

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 2 Terminated
17 enrolled 3 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡